Cadian Capital Management’s Biogen BIIB Stock Holding History

Cadian Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-138,260	Closed	-$39.2M	–	45
2016 Q4	$39.2M	Buy	138,260 +13,260	+11%	+$3.93M	2.09%	18
2016 Q3	$39.1M	Buy	125,000 +60,000	+92%	+$17.8M	2.06%	18
2016 Q2	$15.7M	Buy	+65,000	New	+$17.1M	0.86%	29
2015 Q4	–	Sell	-50,000	Closed	-$14.6M	–	101
2015 Q3	$14.6M	Hold	50,000	–	–	0.53%	51
2015 Q2	$20.2M	Hold	50,000	–	–	0.59%	37
2015 Q1	$21.1M	Buy	50,000 +10,000	+25%	+$3.94M	0.57%	34
2014 Q4	$13.6M	Buy	+40,000	New	+$12.9M	0.34%	51
2014 Q3	–	Sell	-40,000	Closed	-$12.6M	–	81
2014 Q2	$12.6M	Sell	40,000 -37,700	-49%	-$11.3M	0.38%	53
2014 Q1	$23.8M	Sell	77,700 -2,300	-3%	-$730K	0.59%	37
2013 Q4	$22.4M	Buy	80,000 +30,000	+60%	+$7.76M	0.58%	39
2013 Q3	$12M	Buy	+50,000	New	+$11.2M	0.35%	52

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Cadian Capital Management's BIIB Position: Q1 2017 in Review

Cadian Capital Management sold out of Biogen (BIIB) in Q1 2017, closing a stake of 138,260 shares — an estimated $39.2M sold.

Cadian Capital Management first reported a position in BIIB in Q3 2013 and held it in 11 quarters. The position peaked at $39.2M in Q4 2016. 1,020 funds tracked by Wall St. Rank hold BIIB as of Q1 2017.

Cadian Capital Management reported no remaining Biogen position as of Q1 2017 after selling out during the quarter.
Cadian Capital Management sold 138,260 Biogen shares in Q1 2017, an estimated $39.2M.
Cadian Capital Management first reported a position in Biogen in Q3 2013 and held it in 11 quarters.
Cadian Capital Management's Biogen position peaked at $39.2M in Q4 2016.
1,020 funds tracked by Wall St. Rank held Biogen as of Q1 2017.

Based on Cadian Capital Management's 13F filing for Q1 2017, filed 12 May 2017.